

Figure 1



a. *Choice of paclitaxel, topotecan or PLD (Caeytx)*
b. *15 mg/kg q3w will be used instead if topotecan is selected and administered at a dose of 1.25 mg/m2 on a 1-5/q3w schedule*
c. *Refer to section 6.1.3 Treatment at disease progression only*


Figure 2

Subgroup		No. of patients	Median PFS, months		HR[a]
			CT	BEV + CT	
All patients		361	**3.4**	**6.7**	0.48
Age, years	**<65**	228	**3.4**	**6.0**	0.49
	≥65	133	**3.5**	**7.8**	0.47
PFI, months[b]	**<3**	96	**2.1**	**5.4**	0.53
	3–6	257	**3.6**	**7.8**	0.46
Measurable disease (cm)	**No (<1)**	74	**3.7**	**7.5**	0.46
	Yes (1–<5)	126	**3.3**	**7.5**	0.50
	Yes (≥5)	161	**3.3**	**6.0**	0.47
Ascites	**Yes**	113	**2.5**	**5.6**	0.40
	No	248	**3.5**	**7.6**	0.48
Chemotherapy	**Paclitaxel**	115	**3.9**	**10.4**	0.46
	PLD	126	**3.5**	**5.4**	0.57
	Topotecan	120	**2.1**	**5.8**	0.32



[a]Unadjusted. [b]Missing n=8

Figure 3


CT
BEV + CT
Patients (%)
0
5
10
15
20
25
30
35
40
45
50
12.6
30.9
p<0.001
11.8
27.3
p=0.001
11.6
31.8
p<0.001
Responders (RECIST and/or CA-125) (n=350)
RECIST Responders (n=287)
CA-125 Responders (n=297)